← Leaderboards
Marcela Valderrama Maus
Massachusetts General Hospital
$16,508,365
Attributed
$17,161,153
Total exposure
7
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $4M · FY2012–25$5M$3.8M$2.5M$1.3M$0
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$17,161,153 · 7
By mechanism
R01$11,602,644 · 4
UG3$2,756,416 · 1
UH3$2,054,733 · 1
K08$747,360 · 1
Top collaborators
- Bryan Choi2 shared
Most similar at Massachusetts General Hospital
Same institution · by research overlap
- Max Jan$1,188,918
- Benjamin Peter Kleinstiver$4,326,064
- Russell James Hubbard Ryan$3,033,509
- Mark Leick$595,456
- Khalid A Shah$15,720,802
Others in their field
Top investigators on “Engineering”
- David Heimbrook · Leidos Biomedical Research, Inc.$265,348,415
- Francis L Halzen · University Of Wisconsin-Madison$239,306,664
- Lisa Garcia Bedolla · University Of California-Berkeley$175,927,128
- Daniel Stanzione · Arizona State University$173,674,275
- Charles Mattias Mountain · Association Of Universities For Research In Astronomy, Inc.$173,157,760
- Kiyoshi Suyehiro · Iodp Management International, Inc$166,539,344
Research focus
EngineeringCellsT-LymphocyteMouse ModelClinical TrialsSolid NeoplasmImmuneAntibodiesTumorNeoplastic CellAntigensChimeric Antigen Receptor T CellsChimeric Antigen ReceptorAntigen TargetingResponseSignal TransductionReceptorImmunotherapyMutationPharmaceutical PreparationsProteinsMediatingLaboratoriesSafety
Grant awards (27)
CAR T cells targeting mesothelin and secreting bispecific antibodies targeting fibroblasts in pancreatic cancer$2,054,733
UH3 · FY2025 · CA · contact PI
Understanding and manipulating programmed cell death (PCD) pathways to facilitate lymphoid tumor killing by CAR T cells$703,154
R01 · FY2025 · CA · contact PI
Bioactivity of CAR T cells secreting T cell engager-anitbodies in humans with glioblastoma$652,851
R01 · FY2025 · CA · contact PI
Novel CAR T cell engineering strategies for effective eradication of solid and liquid tumors$633,633
R01 · FY2025 · CA · contact PI
CAR T cells targeting mesothelin and secreting bispecific antibodies targeting fibroblasts in pancreatic cancer$1,342,869
UG3 · FY2024 · CA · contact PI
Understanding and manipulating programmed cell death (PCD) pathways to facilitate lymphoid tumor killing by CAR T cells$667,996
R01 · FY2024 · CA · contact PI
Efficacy and immune effects of anakinra prophylaxis for neurologic toxicity and cytokine release syndrome in patients with lymphoma receiving axicabtagene ciloleucel$662,340
R01 · FY2024 · CA · contact PI
Bioactivity of CAR T cells secreting T cell engager-anitbodies in humans with glioblastoma$652,725
R01 · FY2024 · CA · contact PI
CAR T cells targeting mesothelin and secreting bispecific antibodies targeting fibroblasts in pancreatic cancer$1,413,547
UG3 · FY2023 · CA · contact PI
Understanding and manipulating programmed cell death (PCD) pathways to facilitate lymphoid tumor killing by CAR T cells$689,091
R01 · FY2023 · CA · contact PI
Efficacy and immune effects of anakinra prophylaxis for neurologic toxicity and cytokine release syndrome in patients with lymphoma receiving axicabtagene ciloleucel$683,255
R01 · FY2023 · CA · contact PI
Overcoming tumor heterogeneity in glioblastoma with multi-targeted CAR T cells secreting bispecific antibodies$545,246
R01 · FY2023 · CA · contact PI
Understanding and manipulating programmed cell death (PCD) pathways to facilitate lymphoid tumor killing by CAR T cells$689,091
R01 · FY2022 · CA · contact PI
Efficacy and immune effects of anakinra prophylaxis for neurologic toxicity and cytokine release syndrome in patients with lymphoma receiving axicabtagene ciloleucel$683,255
R01 · FY2022 · CA · contact PI
Overcoming tumor heterogeneity in glioblastoma with multi-targeted CAR T cells secreting bispecific antibodies$556,372
R01 · FY2022 · CA · contact PI
Understanding and manipulating programmed cell death (PCD) pathways to facilitate lymphoid tumor killing by CAR T cells$720,152
R01 · FY2021 · CA · contact PI
Efficacy and immune effects of anakinra prophylaxis for neurologic toxicity and cytokine release syndrome in patients with lymphoma receiving axicabtagene ciloleucel$697,200
R01 · FY2021 · CA · contact PI
Overcoming tumor heterogeneity in glioblastoma with multi-targeted CAR T cells secreting bispecific antibodies$556,372
R01 · FY2021 · CA · contact PI
Efficacy and immune effects of anakinra prophylaxis for neurologic toxicity and cytokine release syndrome in patients with lymphoma receiving axicabtagene ciloleucel$697,200
R01 · FY2020 · CA · contact PI
Overcoming tumor heterogeneity in glioblastoma with multi-targeted CAR T cells secreting bispecific antibodies$556,357
R01 · FY2020 · CA · contact PI
Overcoming tumor heterogeneity in glioblastoma with multi-targeted CAR T cells secreting bispecific antibodies$556,354
R01 · FY2019 · CA · contact PI
Designer antigen receptors to re-direct T cells to the NY-ESO-1 tumor antigen$149,472
K08 · FY2016 · CA · contact PI
Designer antigen receptors to re-direct T cells to the NY-ESO-1 tumor antigen$149,471
K08 · FY2015 · CA · contact PI
Designer antigen receptors to re-direct T cells to the NY-ESO-1 tumor antigen$1
K08 · FY2015 · CA · contact PI
Designer antigen receptors to re-direct T cells to the NY-ESO-1 tumor antigen$149,472
K08 · FY2014 · CA · contact PI
Designer antigen receptors to re-direct T cells to the NY-ESO-1 tumor antigen$149,472
K08 · FY2013 · CA · contact PI
Designer antigen receptors to re-direct T cells to the NY-ESO-1 tumor antigen$149,472
K08 · FY2012 · CA · contact PI